Citadel Advisors’s Kyverna Therapeutics KYTX Stock Holding History
Bought
Maintained
Sold
Other funds holding KYTX
ACM
Citadel Advisors's KYTX Position: Q3 2026 in Review
Citadel Advisors reduced its Kyverna Therapeutics (KYTX) stake by 7.2% in Q3 2026, selling an estimated $83.6K and leaving 137,034 shares worth $932K. The position accounts for ﹤0.01% of the portfolio, ranked #8653.
Citadel Advisors first reported a position in KYTX in Q1 2024 and has held it in 11 quarters since. The position peaked at $13M in Q1 2024. 127 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.
- Citadel Advisors held 137,034 shares of Kyverna Therapeutics worth $932K as of Q3 2026.
- Citadel Advisors sold 10,593 Kyverna Therapeutics shares in Q3 2026, an estimated $83.6K.
- Kyverna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #8653 holding.
- Citadel Advisors first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 11 quarters since.
- Citadel Advisors's Kyverna Therapeutics position peaked at $13M in Q1 2024.
- 127 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.